Christian S. Head

Otolaryngology | Surgical Oncology
2767 Olive Hwy
Oroville, CA 95966

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Journal: PloS one
Published: April 23, 2012
Showing 1-1 of 1

Last Updated: 09/26/2026